My Treatment Approach: Androgen Receptor Inhibitors and the Evolving Treatment Paradigm in Castration-Sensitive Prostate Cancer

home / insights / my-treatment-approach-androgen-receptor-inhibitors-and-the-evolving-treatment-paradigm

Stephen J. Freedland, MD, and Eleni Efstathiou, MD, PhD, examine the role of androgen receptor inhibitors, emphasize the significance of early intervention and biomarkers, and evaluate recent developments in the treatment paradigm for castration-sensitive prostate cancer.

2 KOLs are featured in this panel.

EP. 1: Testing Principes and Benefits of Early Intervention in Castration-Sensitive Prostate Cancer

Stephen J. Freedland, MD;Eleni Efstathiou, MD, PhD
June 26th 2024

Key opinion leaders examine the principles and advantages of early intervention strategies for patients with castration-sensitive prostate cancer.

2 KOLs are featured in this panel.

EP. 2: Risk Stratification and Prognostic Markers in castration-sensitive prostate cancer

Stephen J. Freedland, MD;Eleni Efstathiou, MD, PhD
June 26th 2024

The panel of prostate cancer experts explores risk stratification methodologies and prognostic markers for castration-sensitive prostate cancer, emphasizing crucial factors that influence patient categorization and treatment decisions.